Aim: To assess the role of Notch activation in predicting bevacizumab efficacy in colorectal cancer (CRC). Materials & methods: Notch activation was evaluated by immunohistochemistry (IHC) on 65 CRC enrolled within randomized clinical trials assessing first-line bevacizumab-based chemotherapy and on 21 CRC treated with chemotherapy alone. Results: Strong Notch (IHC 3+) activation was negatively associated with response (18 vs 62% in low Notch cases [IHC 0, 1, 2+]; p = 0.016), progression-free survival (4.9 vs 12.1 months; p = 0.002) and overall survival (19.3 vs 30.4 months; p = 0.039). No correlation was found between Notch activation and clinical outcome in CRC treated with chemotherapy alone. Conclusion: A potential role of Notch activation in the antitumor activity of bevacizumab could be hypothesized.
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer / Negri, F.V., Crafa, P., Pedrazzi, G., Bozzetti, C., Lagrasta, C.A.M., Gardini, G., Tamagnini, I., Bisagni, A., Azzoni, C., Bottarelli, L., Graiani, G., Romano, I., Porzio, R., Bacchini, G.P., Paties, C., Tomasello, G., Marchetti, G.M., Fanello, S., Pinto, C., Sala, R., et al.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 11:23(2015), pp. 3167-3174. [10.2217/fon.15.218]
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer
CRAFA, Pellegrino;PEDRAZZI, Giuseppe;LAGRASTA, Costanza Anna Maria;BISAGNI, ALESSANDRA;AZZONI, Cinzia;BOTTARELLI, Lorena;GRAIANI, Gallia;ROMANO, IDA;PORZIO, Rosa;BACCHINI, Gian Paolo;TOMASELLO, Gianluca;MARCHETTI, Giovanni Maria;SALA, Roberto;ARDIZZONI, Andrea
2015-01-01
Abstract
Aim: To assess the role of Notch activation in predicting bevacizumab efficacy in colorectal cancer (CRC). Materials & methods: Notch activation was evaluated by immunohistochemistry (IHC) on 65 CRC enrolled within randomized clinical trials assessing first-line bevacizumab-based chemotherapy and on 21 CRC treated with chemotherapy alone. Results: Strong Notch (IHC 3+) activation was negatively associated with response (18 vs 62% in low Notch cases [IHC 0, 1, 2+]; p = 0.016), progression-free survival (4.9 vs 12.1 months; p = 0.002) and overall survival (19.3 vs 30.4 months; p = 0.039). No correlation was found between Notch activation and clinical outcome in CRC treated with chemotherapy alone. Conclusion: A potential role of Notch activation in the antitumor activity of bevacizumab could be hypothesized.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
